Eyenovia Inc Company Overview
About Eyenovia Inc
Eyenovia (NASDAQ:EYEN) is pioneering a new approach to eye care through its development of microdosing technology for ophthalmic treatments. The company is traded on the NASDAQ exchange. Eyenovia focuses on creating advanced therapeutic solutions using its proprietary Optejet device, which administers precise microdoses of medication to the eye, potentially enhancing efficacy and reducing side effects. Their pipeline includes innovative treatments for myopia progression, presbyopia, and other eye-related conditions, aiming to provide user-friendly alternatives to traditional eye drops. By prioritizing precision and patient convenience, Eyenovia is set on transforming how eye conditions are managed, with a commitment to enhancing patients' lives through cutting-edge ocular science.
Snapshot
Operations
Produtos e/ou serviços de Eyenovia Inc
- Optejet: Precision ocular delivery platform designed for consistent micro-dose administration, enhancing therapeutic effect and reducing side effects for various eye conditions.
- Microstat: Investigational formulation targeting pharmacologic mydriasis in a more efficient and comfortable method for eye examinations.
- MicroPine: A clinical-stage program intended to slow myopia progression in children through targeted micro-dosing of atropine.
- MicroLine: A proposed treatment focusing on presbyopia, aiming to improve near vision through a proprietary dosing method.
- Strategic Collaborations: Partnerships with pharmaceutical companies to apply micro-dosing technology to diverse therapeutic areas and innovations.
- Research and Development: Continual innovation in ocular drug delivery and formulation to expand treatment options for various eye diseases.
equipe executiva do Eyenovia Inc
- Mr. Michael M. RowePrincipal Financial Officer, CEO, President & Director
- Dr. Tsontcho Ianchulev M.D., M.P.H., MPHCo-Founder & Executive Director
- Mr. Bren KernChief Operating Officer
- Mr. Norbert LoweSenior Vice President of Commercial Operations
- Mr. Enrico BrambillaSenior Vice President of R&D
- Alexander LoboInvestor Contact